Menu
Date: 22-23 May 2025
Language: English
Key poins:
Welcome to the Global Pulmonary Health Conference 2025 in the dynamic city of Munich, Germany! We are thrilled to bring together leading experts, researchers, and healthcare professionals dedicated to advancing pulmonary health. Over two days, immerse yourself in cutting-edge research, explore innovative treatment approaches, and engage in meaningful discussions. Join us to network with colleagues, exchange ideas, and collaborate on solutions that will shape the future of pulmonary health. Let’s work together to improve respiratory care worldwide!
Welcome to the Global Pulmonary Health Conference 2025 in the dynamic city of Munich, Germany! This premier event gathers esteemed professionals and newcomers alike to delve into the latest advancements and challenges in pulmonary health. Over two days, you will have the opportunity to explore topics ranging from innovative therapies for COPD to the role of genetics in asthma management. Engage in discussions on pulmonary rehabilitation, air quality impacts, and the latest trends in lung cancer treatment. Sessions will also cover telemedicine in pulmonary care, pediatric pulmonology, and global strategies for tuberculosis control. Join us to foster innovation, collaboration, and excellence in the field of pulmonary health. We look forward to an enriching and impactful summit!
Located in the heart of Bavaria, Munich is renowned for its contributions to biomedical research and innovation. The city boasts a thriving ecosystem of research institutions, pharmaceutical companies, and healthcare providers dedicated to advancing pulmonary health. Munich offers state-of-the-art conference facilities, historic landmarks, and a vibrant cultural scene that make it an ideal setting for international conferences. Delegates can explore the city’s rich history, picturesque architecture, and world-class museums. Experience Munich’s blend of tradition and modernity, where scientific excellence meets cultural sophistication, ensuring a memorable and productive summit experience.
© 2023-2024 VNA International IČO: 09236147
Global Pulmonary Health Summit 2025
Rose-Marie Jenvert has over 20 years of experience within the medical device, pharma and biotechnology industry, and is currently working as Biocompatibility Specialist at Veranex, located in Lund Sweden. Rose-Marie is an experienced method developer of in vitro methods and holds a MSc in Molecular Biology and a PhD in Cell Biology. She has experience in performing biological evaluations of medical devices and has previously worked as study director for biocompatibility studies, setting up testing strategies and coordinating biological and chemical testing. She also has hands-on experience of testing different materials and medical devices.
Rose-Marie is actively working as an expert in ISO/TC194 WG8 with updating of the standards for skin sensitization and skin irritation (ISO 10993-10 and -23), and is also involved in the work of WG5, the standard for cytotoxicity.
Michael works as a Biocompatibility Specialist at Sonova AG, focusing on evaluating and implementing biocompatibility testing strategies for medical devices and materials. Furthermore, he has experience as a project manager in Product Stewardship, ensuring safety and regulatory compliance in the chemical sector. Since his Ph.D. in environmental toxicology, Michael consistently emphasized the development and application of innovative in vitro methods, such as the development of novel cell lines for toxicity screening. He will share practical insights and present case studies about his experience using in vitro sensitization methods for medical devices.
Jan Wirsching has many years of experience in the medical device industry working in the field of biocompatibility and material compliance, and is currently working at Maquet Cardiopulmonary GmbH, a Getinge Company. Jan holds degrees in Molecular Medicine and Toxicology. He has experience in performing biological evaluations, toxicological risk assessments and material compliance evaluations for a wide range of devices, including combination products. Jan Wirsching is actively working as an expert in the development of a guideline on characterizing and assessing nanomaterials in medical devices and in vitro diagnostics (VDI 5709).
Theme: Complexity of Combination Products: Drug Device Interactions
– What are drug device interactions and how to investigate them?
– How do drug device interactions influence the biological risk assessment?
– Case Study: Biological risk assessment of a Heparin/Albumin-coated combination product
Fabian Kriegel is currently Head of Material Development and Biocompatibility at Carl Zeiss Meditec AG, where he leads a dynamic team focused on the development of biocompatible materials, particularly for ophthalmic applications. Together with his dedicated team, Fabian ensures the seamless implementation of testing strategies in accordance with international standards for safety and efficacy. His expertise also extends to guiding projects through the complex processes of international regulatory approval, facilitating the acceptance of medical devices on a global scale.
Prior to his current role, Fabian held positions such as GLP Study Director and Genetic Toxicology Laboratory Manager in the pharmaceutical industry. Academically, Fabian has contributed to various research areas such as nanomaterial toxicity, analytical chemistry and computational biology. In addition, he is recognized as a European Registered Toxicologist and an active member of various toxicology societies.
